Skip to main content
Guilin Layn Natural Ingredients Corp. logo

Guilin Layn Natural Ingredients Corp. — Investor Relations & Filings

Ticker · 002166 ISIN · CNE1000006W1 LEI · 836800QPT86VD3Q4RP50 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,339 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002166

About Guilin Layn Natural Ingredients Corp.

https://www.layn.com.cn

Guilin Layn Natural Ingredients Corp. specializes in the research, development, and large-scale production of plant-based sweeteners and functional botanical extracts. The company is a global leader in the extraction of monk fruit (Luo Han Guo) and stevia, providing natural, zero-calorie sweetening solutions to the food and beverage industry. Its product portfolio extends to a wide range of natural ingredients, including tea extracts, citrus derivatives, and polyphenols designed for applications in dietary supplements, pharmaceuticals, personal care, and animal nutrition. Layn maintains a vertically integrated supply chain, emphasizing sustainable sourcing and advanced extraction technologies to ensure high purity and quality standards. With a focus on innovation and global distribution, the company supports manufacturers in meeting consumer demand for clean-label and health-oriented products.

Recent filings

Filing Released Lang Actions
关于公司控制权变更、发行股份购买资产并募集配套资金暨关联交易事项的进展公告
Capital/Financing Update Classification · 85% confidence The document is a progress announcement (“进展公告”) on a transaction involving control change, issuance of shares to purchase assets and the associated fundraising. It is not the primary transaction pre-announcement or proxy statement, nor is it a formal M&A proxy or takeover bid document. Rather, it provides an update on financing and capital structure changes (issuing shares for asset acquisition and raising matching funds). Therefore it best fits the “Capital/Financing Update” category (CAP).
2026-05-22 Chinese
莱茵生物2025年度内部控制审计报告
Audit Report / Information Classification · 92% confidence The document is titled “2025年度内部控制审计报告” addressed from an external audit firm (“致同会计师事务所”) to the company’s shareholders. It presents the auditor’s opinion on the effectiveness of the company’s internal control over financial reporting and discloses material control deficiencies. This is a standalone audit report, not a full annual report or mere announcement. Therefore it falls under the Audit Report / Information category. FY 2025
2026-03-30 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is a detailed policy document titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management' of 桂林莱茵生物科技股份有限公司. It outlines the principles, mechanisms, structure, adjustment, and payment of remuneration for directors and senior management. It references relevant laws and company articles but does not contain financial statements or performance data. The document is a governance-related policy on executive compensation rather than a report or announcement of financial results or changes in management. Therefore, it fits the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-03-30 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 桂林莱茵生物科技股份有限公司 regarding a change in accounting policies in response to a new accounting standard issued by the Ministry of Finance of China. It explains the reasons for the change, the effective date, and the expected impact on the company's financials. The document is relatively short (1202 characters) and does not contain any financial statements or detailed financial data. It is not a full annual or interim report, nor an audit report. It is a regulatory announcement about accounting policy changes, which fits best under Regulatory Filings (RNS).
2026-03-30 Chinese
董事会关于2025年度证券投资情况的专项说明
Board/Management Information Classification · 95% confidence The document is a detailed explanation from the company's board regarding the securities investment situation for the year 2025. It includes specific investment approvals, investment amounts, accounting details, internal control execution, and a board statement on the investment activities. The document is not a full annual or interim financial report but a focused disclosure on securities investment activities and related governance. It is not an announcement of voting results, management changes, or a general regulatory filing. The content aligns with a specialized board/management information disclosure about securities investment activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2026-03-30 Chinese
董事会关于独立董事独立性自查情况的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the board regarding the independence of the company's independent directors, referencing regulatory rules and internal governance documents. It is a specialized opinion on director independence, not a full report, financial statement, or announcement of voting results. It does not contain financial data or meeting results. This fits best under Board/Management Information (MANG) as it relates to board member status and governance compliance.
2026-03-30 Chinese

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.